{"slug":"api-magentlab-com-api-calc-gipss-ec5a41","title":"Tefferi 2018 GIPSS for primary myelofibrosis","host":"api.magentlab.com","method":"POST","resource":"https://api.magentlab.com/api/calc/gipss","category":"other","description":"Tefferi 2018 GIPSS for primary myelofibrosis: karyotype (favorable 0, unfavorable 1, VHR 2; caller assigns the three-tier class), absence of type 1/like CALR 1, ASXL1 1, SRSF2 1, U2AF1Q157 1 (not S34); max 6. Low 0, intermediate_1 1, intermediate_2 2, high ≥3. Published median (5-year) survivals 26.","price_listed":0.005,"price_asked":0.007,"state":"overcharges","state_label":"Asked 1.4x its listed price for its own example","checks_7d":1,"answered_7d":1,"latency_ms_median":269,"reported_calls_30d":0,"reported_payers_30d":0,"networks":["eip155:8453"],"badge":"unverified","paid_checks_7d":0,"paid_ok_7d":0,"example_input":{"body":{"items":[{"asxl1_mutated":false,"calr_type1_like":true,"karyotype":"favorable","srsf2_mutated":false,"u2af1_q157_mutated":false},{"asxl1_mutated":false,"calr_type1_like":true,"karyotype":"favorable","srsf2_mutated":false,"u2af1_q157_mutated":false}]},"method":"POST","type":"http"},"output_schema":{"$schema":"https://json-schema.org/draft/2020-12/schema","properties":{"input":{"additionalProperties":false,"properties":{"body":{"additionalProperties":false,"properties":{"items":{"items":{"properties":{"asxl1_mutated":{"description":"ASXL1 mutation as assigned by the caller (Tefferi 2018). true scores 1. magent does not sequence.","type":"boolean"},"calr_type1_like":{"description":"Presence of a type 1/like CALR mutation as assigned by the caller (Tefferi 2018). false (absence) scores 1. true scores 0. Type 2/like CALR, JAK2, MPL, and triple-negative are absence of type 1/like CALR. magent does not sequence.","type":"boolean"},"karyotype":{"description":"Tefferi 2018 revised three-tier karyotype as assigned by the caller (mutually exclusive). favorable is a normal karyotype or sole 13q−, +9, 20q−, chromosome 1 translocation/duplication, or sex chromosome abnormality including −Y and scores 0. unfavorable is all other abnormalities and scores 1. vhr is very high risk: single/multiple −7, i(17q), inv(3)/3q21, 12p−/12p11.2, 11q−/11q23, +21, or other autosomal trisomies not including +8/+9 and scores 2. magent does not karyotype.","enum":["favorable","unfavorable","vhr"],"type":"string"},"srsf2_mutated":{"description":"SRSF2 mutation as assigned by the caller (Tefferi 2018). true scores 1. magent does not sequence.","type":"boolean"},"u2af1_q157_mutated":{"description":"U2AF1 Q157 mutation (Q157P or Q157R) as assigned by the caller (Tefferi 2018). true scores 1. U2AF1 S34 does not score. magent does not sequence.","type":"boolean"}},"required":["karyotype","calr_type1_like","asxl1_mutated","srsf2_mutated","u2af1_q157_mutated"],"type":"object"},"maxItems":25,"minItems":1,"type":"array"}},"required":["items"],"type":"object"},"headers":{"additionalProperties":{"type":"string"},"type":"object"},"method":{"const":"POST","type":"string"},"type":{"const":"http","type":"string"}},"required":["type","method"],"type":"object"},"output":{"properties":{"example":{"type":"object"},"type":{"type":"string"}},"required":["type"],"type":"object"}},"required":["input"],"type":"object"},"history":[{"day":"2026-09-28","reachable":true,"status":402,"valid_402":true,"asked_usdc":0.007,"price_match":false,"latency_ms":269,"error":null}],"description_full":"Tefferi 2018 GIPSS for primary myelofibrosis: karyotype (favorable 0, unfavorable 1, VHR 2; caller assigns the three-tier class), absence of type 1/like CALR 1, ASXL1 1, SRSF2 1, U2AF1Q157 1 (not S34); max 6. Low 0, intermediate_1 1, intermediate_2 2, high ≥3. Published median (5-year) survivals 26.4 y (94%), 8.0 y (73%), 4.2 y (40%), 2 y (14%). Not DIPSS or MIPSS70-plus. magent does not karyotype or sequence.","last_updated":"2026-09-28T15:09:46.28Z","schemes":["exact"]}